San Francisco Suspect Arrested After Molotov Cocktail Attack on OpenAI CEO Sam Altman's Home 
Lumentum Holdings Rides AI Wave With Order Book Filled Through 2028 
Chinese Cars in Europe: Consumer Trust Is Shifting Fast 
Kia Cuts EV Sales Target for 2030 Amid Slowing Demand and U.S. Policy Shifts 
Pony.ai, Uber, and Verne Launch Europe's First Commercial Robotaxi Service in Zagreb 
BHP's Incoming CEO Visits China Amid Pricing Dispute with CMRG 
Pilots Fear Retaliation for Refusing Middle East Flights Amid Ongoing Conflict 
Goldman Sachs, ANZ Cut Oil Forecasts Amid U.S.-Iran Ceasefire Hopes 
Alibaba Shares Slide as Jefferies Slashes Price Target Over AI Spending and Business Losses 
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts 
TSMC Posts Strong Q1 2025 Revenue, Riding AI Chip Demand Wave 
Abbott Laboratories Ordered to Pay $53 Million in Premature Infant Formula Lawsuit 
OpenAI Addresses Security Vulnerability in macOS App Certification Process 
U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market 
NIO ES9 SUV Launch Sends HK Shares Down 7% Despite Bold Pricing Strategy 
MATCH Act: How New U.S. Chip Legislation Could Freeze China's Semiconductor Ambitions 
SanDisk Joins Nasdaq-100, Replacing Atlassian on April 20 
BRISBANE, Calif., Oct. 31, 2016 -- KaloBios Pharmaceuticals, Inc. (OTC:KBIO), a biopharmaceutical company focused on advancing medicines for patients with neglected and rare diseases, announced that Cameron Durrant, MD, chairman and CEO, will present how innovative pricing approaches, such as the company’s Responsible Pricing Model, can fortify existing incentives to bring therapies to the U.S. for neglected diseases during the Priority Review Voucher (PRV) Summit in Arlington, Va., November 2-3, 2016.
Dr. Durrant will also participate in a separate panel to discuss PRVs as a model to support the research and development of important medicines.
“The current PRV system is enlightened policy driving both immediate help, and future advancements, for neglected disease patients,” said Dr. Durrant. “We look forward to engaging in the conversation around serving the public health through these effective FDA incentives and responsible drug pricing.”
Details of the presentation and panel follow:
Title: Tackling Neglected Diseases through Responsible Pricing
Date: Wednesday, November 2, 2016
Time: 3:00 – 3:45 p.m. EDT
Presenter: Dr. Cameron Durrant, KaloBios Pharmaceuticals
Title: Panel: Priority Review Vouchers: A New Paradigm for Funding Research
Date: Wednesday, November 2, 2016
Time: 4:15 – 5:15 p.m. EDT
Participants: Xi Chen, PhD, Adena Partners Management; Dr. Cameron Durrant, KaloBios Pharmaceuticals; Charles Keller, MD, Children’s Cancer Therapy Development Institute; Curt H. LaBelle, MD, Global Health Investment Fund
For more information on the conference, please visit http://exlevents.com/priorityreviewvoucher/.
About KaloBios Pharmaceuticals, Inc.
KaloBios Pharmaceuticals, Inc. (OTC:KBIO) is an emerging biopharmaceutical company focused on advancing medicines for patients with neglected and rare diseases through innovative and responsible business models. Lead compounds in the KaloBios portfolio are benznidazole for the potential treatment of Chagas disease in the U.S., and the proprietary monoclonal antibodies, lenzilumab and ifabotuzumab (formerly KB004), for the potential treatment of various solid and hematologic cancers such as CMML and potentially JMML. For more information, visit www.kalobios.com.
CONTACT: Investors: Kim Sutton Golodetz O: 212-838-3777 [email protected] Bruce Voss O: 310-691-7100 [email protected] Media: Lisa Guiterman O: 301-217-9353 C: 202-330-3431 [email protected]
